Tinubu Square Appoints Aurelien Pelletier as Chief Product & Technology Officer
26.1.2022 16:00:00 EET | Business Wire | Press release
Tinubu Square, a proven SaaS solutions editor and a leader in enabling Credit Insurance & Surety digital transformation, is expanding. To sustain its current growth, Tinubu recently made acquisitions, onboarded new technologies and is equipping itself with the capabilities to achieve its ambitions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005498/en/
Tinubu Square - Aurelien PELLETIER - CPTO
This is reflected in the investments made in its products, but also in the evolution of its organization, such as the arrival of Aurélien Pelletier as Chief Product & Technology Officer, a recognized specialist in cutting-edge digital technology.
His role will be to accelerate Tinubu’s progression as a high-performance "software factory" and drive its products' evolution toward an end-to-end technological platform, a "Digital Highway" for our Credit Insurance & Surety customers connecting their entire ecosystem.
Tinubu’s endeavor and our new CPTO’s mission are about fostering flexibility and agility for a faster and still highly reliable technical delivery. In short, uphold our promise, "You are an insurer, and you want to focus on your field of expertise. We can bring to you the best technology to enable you do your business more efficiently."
Aurélien has more than 20 years of experience working in the tech industry providing best-in-class services, and a proven 10-year track record at C-level positions.
At the beginning of the millennium, he worked in the software design and delivery consulting services field for Atos as a technical architect working on innovation. In 2012, he joined Sfeir as CTO to advance its position into a leader on digital transformation and cloud computing projects. Then, from 2017 to 2020, he became the CTO of PrestaShop, a leading open-source e-commerce solution, where he defined and led the tech vision and strategy of the company.
With his deep experience in Agile methodologies, DevOps, continuous delivery, open sources, cloud computing and Web APIs, Aurélien is not only the perfect match for Tinubu’s objectives, but the love for his fields of expertise is also what drives him.
After having worked on all types of information system architectures, today he has developed a passion for organizational architecture – and the many bridges that exist between these two specialties.
“We are continuously working at strengthening the technological side of Tinubu’s solutions and having on board someone like Aurélien who masters the most advanced technologies and methodologies is what we were looking for. He is a great asset and resource to keep improving our ability to bring best-in-class technology to our customers through our SaaS platform,” declares Olivier Placca, Deputy CEO of Tinubu Square.
“I have known Tinubu for a long time and have a lot of trust in the executive team and its vision. I am excited by the ambitions, the potential and the international scope that define Tinubu. I think that combination is a very strong point of attraction for new talents and for those who already have experience working on a global market,” states Aurélien Pelletier.
About Tinubu Square – www.tinubu.com — @TinubuGroup
Tinubu Square is the industry-leading SaaS platform vendor, enabling Credit Insurance & Surety digital transformation. For more than 20 years, Tinubu Square has provided Credit & Surety insurers across the globe with software and services allowing them to offer best-in-class customer experience, as well as significantly reduce their exposure to risk and their financial, operational, and technical costs. Tinubu Square has an international footprint with customers in over 20 countries, including 30 of the top 60 worldwide Credit & Surety underwriters.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005498/en/
Contact information
Press contact
Tinubu Square: Lotta Bonde
lbe@tinubu.com
Phone: +33 1 55 95 85 85
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom